OCCIDENT’s portfolio company Tubulis raises more than €300 million
OCCIDENT participated in this incredible Series C round led by Venrock Healthcare Capital Partners to further develop antibody-drug conjugates (ADCs).
News
Thermosome reports encouraging data from Phase I trial
Early clinical data show encouraging efficacy and safety for THE001, supporting advancement into Phase 2 trials in advanced soft tissue sarcoma.
Algiax presented promising results from Phase 2 study
The study with the lead compound AP-325 shows meaningful pain reduction in patients with peripheral post-surgical neuropathic pain, with fewer side effects.
Tubulis’ second drug candidate enters clinical evaluation
Tubulis advances its pipeline as TUB-030, a next-generation ADC targeting advanced solid tumors, enters Phase I/IIa trial.
Tubulis enters into collaboration with Gilead Sciences
The agreement, valued at up to $415 million, combines Gilead's long-standing expertise with Tubulis' innovative technology to advance ADC treatment for solid tumors.
Thermosome presents encouraging first clinical data
Phase I Trial data show safety and potential efficacy in heavily pre-treated soft tissue sarcoma patients. In 4 out of 6 patients, the disease remained stable per RECIST.
Initial Investment in Lymphatica
OCCIDENT participates in the € 17.9 million Series B funding round of Lausanne-based Lymphatica Medtech that develops novel treatment options for patients suffering from lymphedema.
Tubulis Receives FDA Fast Track Designation
Tubulis' TUB-040, an ADC for platinum-resistant ovarian cancer, receives FDA Fast Track, expediting its development in Phase I/IIa trials to address urgent cancer treatment needs.
Tubulis Doses First Patient in Phase I/IIa Trial for TUB-040
UB-040 targets an overexpressed antigen in ovarian and lung adenocarcinoma. The trial will enroll up to 140 patients across the US, UK, and Europe.